Analysts expect Chromadex Corp (NASDAQ:CDXC) to report earnings per share (EPS) of ($0.11) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Chromadex’s earnings, with the lowest EPS estimate coming in at ($0.15) and the highest estimate coming in at ($0.08). Chromadex posted earnings of ($0.15) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 26.7%. The company is expected to issue its next quarterly earnings results on Thursday, March 5th.
According to Zacks, analysts expect that Chromadex will report full year earnings of ($0.52) per share for the current year, with EPS estimates ranging from ($0.56) to ($0.47). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.15) per share, with EPS estimates ranging from ($0.27) to $0.09. Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Chromadex.
Chromadex (NASDAQ:CDXC) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.12) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.12). Chromadex had a negative net margin of 74.55% and a negative return on equity of 137.97%. The company had revenue of $12.05 million during the quarter, compared to the consensus estimate of $11.66 million.
Shares of Chromadex stock traded down $0.08 on Monday, reaching $3.56. 196,200 shares of the stock were exchanged, compared to its average volume of 221,353. The firm’s 50 day moving average is $3.27 and its 200-day moving average is $3.96. Chromadex has a one year low of $2.68 and a one year high of $4.95. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.41 and a current ratio of 3.30. The firm has a market cap of $216.86 million, a PE ratio of -5.84 and a beta of 1.40.
In other news, CEO Robert N. Fried purchased 10,000 shares of the business’s stock in a transaction dated Thursday, November 14th. The stock was bought at an average price of $3.20 per share, with a total value of $32,000.00. Corporate insiders own 11.60% of the company’s stock.
Large investors have recently modified their holdings of the stock. Uniplan Investment Counsel Inc. bought a new position in Chromadex in the 2nd quarter valued at approximately $3,279,000. BlackRock Inc. lifted its stake in Chromadex by 15.4% in the 2nd quarter. BlackRock Inc. now owns 2,238,654 shares of the company’s stock valued at $10,410,000 after purchasing an additional 298,126 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Chromadex by 377.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 44,807 shares of the company’s stock valued at $208,000 after purchasing an additional 35,418 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Chromadex by 8.1% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 91,370 shares of the company’s stock valued at $425,000 after purchasing an additional 6,880 shares during the last quarter. Finally, Tieton Capital Management LLC lifted its stake in Chromadex by 5.1% in the 2nd quarter. Tieton Capital Management LLC now owns 1,322,570 shares of the company’s stock valued at $6,150,000 after purchasing an additional 64,680 shares during the last quarter. 19.49% of the stock is owned by institutional investors and hedge funds.
Chromadex Company Profile
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.
See Also: What are catch-up contributions?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.